Our client:

Oxford Biomedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and bioprocessing. The Company was one of the first in the UK biotech sector to go public and has been well-respected in its field for many years.

 

The challenge:

As its strategy shifted towards bioprocessing, Oxford Biomedica was looking to increase the US investment expertise on its Board and appointed The RSA Group to find a new non-executive director. As well as US experience, the individual needed experience in scaling biological manufacturing and be able to run the Board’s audit committee. The Company also wanted to increase the diversity of its Board.

 

 

How our approach made a difference:

By understanding the characteristics and expertise that the client needed, we were able to carry out an efficient and successful global search. The consultants began by looking for companies that had had a similar trajectory to the one Oxford Biomedica was working towards and identifying board members with the skills and experience needed. As a result, a shortlist was produced four months from our appointment and the appointee attended their first board meeting less than a month later. The individual had excellent credentials as well as extensive experience in the investment community and in running audit committees.

 

Share this: